ADHD medications fall into two broad categories: stimulants and non-stimulants. Stimulants are the first-line treatment and work for the majority of people, while non-stimulants offer alternatives for those who can’t tolerate stimulants or need additional coverage. Within those two categories, there are distinct drug classes, different delivery systems, and a handful of off-label options worth knowing about.
Stimulants: The Two Main Classes
All stimulant medications for ADHD are built on one of two active ingredients: methylphenidate or amphetamine. Both increase the availability of dopamine and norepinephrine in the brain, the two chemical messengers most involved in attention and impulse control. Despite doing similar work, they achieve it through slightly different mechanisms, which is why some people respond better to one than the other.
Methylphenidate primarily blocks the recycling of dopamine and norepinephrine back into nerve cells, leaving more of those chemicals active in the spaces between neurons. Amphetamine does that too, but it goes further: it also triggers nerve cells to release extra dopamine from their internal stores and slows down the enzyme that breaks dopamine apart. The net result is that amphetamine-based medications tend to produce a somewhat stronger boost in dopamine levels, though both classes show comparable effects on attention and behavior in clinical imaging studies.
Methylphenidate-Based Medications
This class includes a wide range of brand-name formulations. Common short-acting versions last roughly 3 to 4 hours per dose and are typically taken two or three times a day. The average daily dose for adults is 20 to 30 mg, and most prescriptions cap at 60 mg per day. Extended-release versions use different delivery technologies to stretch coverage across the day. One popular system (used in Concerta) releases an initial dose quickly, then slowly pushes out the rest over about 12 hours using an osmotic pump built into the tablet.
Amphetamine-Based Medications
The amphetamine side includes mixed amphetamine salts (Adderall), dextroamphetamine (Dexedrine), and lisdexamfetamine (Vyvanse). Extended-release mixed amphetamine salts use a bead system where 50% of the medication releases immediately and the other 50% releases about four hours later, mimicking the effect of taking two separate doses. Lisdexamfetamine is a prodrug, meaning your body has to convert it into its active form after you swallow it, which creates a smoother onset and makes it harder to misuse.
All stimulant medications are classified as Schedule II controlled substances by the DEA, meaning they carry a recognized potential for dependence. This classification affects how they’re prescribed: you typically can’t get automatic refills, and some states require in-person visits for each new prescription.
Immediate-Release vs. Extended-Release
The difference between immediate-release (IR) and extended-release (XR or ER) formulations isn’t about what drug you’re taking. It’s about how long each dose works. Immediate-release stimulants have a half-life of roughly two hours for methylphenidate, meaning the drug’s concentration in your blood drops by half every two hours. In practice, a single IR dose covers about 3 to 4 hours, so most people need two or three doses spaced across the day.
Extended-release formulations were designed to eliminate that midday dosing problem. They use coatings, beads, or osmotic systems to meter out the medication over 8 to 12 hours with a single morning dose. The trade-off is less flexibility: if you need coverage only for specific parts of the day (a morning meeting, an evening class), short-acting versions let you target those windows more precisely. Many people use a combination, taking an extended-release dose in the morning with a small IR booster in the afternoon if coverage fades too early.
Non-Stimulant Medications
Non-stimulants are not controlled substances, which makes prescribing and refilling simpler. They’re typically considered when stimulants cause intolerable side effects, when there’s a history of substance use concerns, or when anxiety or tics make stimulants a poor fit. They generally take longer to reach full effectiveness, often several weeks, compared to the near-immediate response most people notice with stimulants.
Norepinephrine Reuptake Inhibitors
Atomoxetine (Strattera) was the first non-stimulant approved specifically for ADHD. It works by blocking the recycling of norepinephrine, which helps with focus and impulse control without directly flooding the brain with dopamine the way stimulants do. Because of this different mechanism, atomoxetine carries virtually no risk of abuse. Viloxazine (Qelbree) is a newer option in this same lane, also targeting norepinephrine.
Alpha-2 Adrenergic Agonists
Guanfacine (Intuniv in its long-acting form) and clonidine (Kapvay in its long-acting form) were originally developed for high blood pressure but turned out to help with ADHD symptoms, particularly hyperactivity, impulsivity, and emotional reactivity. They work by activating receptors in the prefrontal cortex that strengthen the brain’s ability to filter distractions and regulate behavior. Some clinicians note that clonidine’s benefit may partly come from a calming, sedative quality rather than a direct effect on attention, which is why guanfacine is often preferred when the primary goal is cognitive improvement. These medications are frequently combined with a stimulant rather than used alone.
Off-Label Options
When first-line treatments don’t work well enough, some prescribers turn to medications approved for other conditions. Bupropion (Wellbutrin), an antidepressant that acts on dopamine and norepinephrine, is the most commonly used off-label choice for ADHD. It works, but the evidence shows it’s less effective than stimulants. One meta-analysis found that stimulants needed to treat only about 2 people for one to show meaningful improvement, while bupropion needed to treat roughly 5 people for the same result. A direct comparison of bupropion against methylphenidate in small studies found no significant difference in effectiveness, but larger reviews have generally concluded stimulants come out ahead.
Modafinil, a wakefulness-promoting drug, has also been investigated for ADHD but is not FDA-approved for that use. It affects different brain pathways than traditional stimulants and remains a less common choice in clinical practice.
Side Effects by Category
Stimulants share a core set of common side effects: reduced appetite, difficulty falling asleep, increased heart rate, and sometimes irritability or anxiety. Studies tracking methylphenidate users found that about 72% reported at least some side effects, though many were mild enough not to require stopping the medication. Appetite suppression and sleep disruption are the two that most frequently lead people to switch medications or adjust timing.
Cardiovascular effects deserve attention across all stimulants. Users of ADHD stimulants show higher rates of arrhythmias, elevated blood pressure, and other cardiovascular events compared to non-users. Psychotic symptoms are rare but real: roughly 1 in 660 people prescribed stimulants develop new-onset psychosis, with amphetamine-based medications carrying slightly higher rates (about 2.8 per 1,000 person-years) compared to methylphenidate (about 1.8 per 1,000 person-years).
Non-stimulants have their own profiles. Atomoxetine commonly causes nausea, dry mouth, and fatigue, especially early in treatment. It can also raise blood pressure modestly. Alpha-2 agonists like guanfacine and clonidine tend to cause drowsiness, dizziness, and low blood pressure, which usually improve over the first few weeks. Because these drugs lower blood pressure, stopping them abruptly can cause a rebound spike, so tapering off is important.
How Prescribers Choose Between Them
The process is more trial and observation than precise science. Most people start with a stimulant, often at the lowest available dose, and adjust upward over several weeks. If methylphenidate doesn’t work well or causes too many side effects, switching to an amphetamine-based option (or vice versa) is standard practice, since response to the two classes doesn’t always overlap. About 70% of people respond well to the first stimulant they try, and the number climbs higher when both classes are attempted.
Non-stimulants typically enter the picture after stimulants have been tried, though they may be the starting point if you have significant anxiety, a tic disorder, active substance use issues, or cardiovascular risk factors that make stimulants less safe. Children under 6 are generally not prescribed stimulants, as safety and efficacy haven’t been established in that age group for most formulations. For adults, the same medication classes apply, though dosing ranges and formulation choices differ. The decision between IR and extended-release often comes down to daily schedule, insurance coverage, and how sensitive you are to the peaks and valleys of shorter-acting drugs.